Shape Therapeutics and Rett Syndrome Research Trust Announce Partnership to Advance a One-Time AI-Designed RNA Editing Therapy for Rett Syndrome

A collaboration will evaluate Shape’s intravenously delivered RNAfix® gene therapy targeting the MECP2 R168X mutation in non-human primates (NHP). The announcement provides early-stage preclinical evaluation progress but does not include efficacy, timelines, or financial impact.

Analysis

A collaboration will evaluate Shape’s intravenously delivered RNAfix® gene therapy targeting the MECP2 R168X mutation in non-human primates (NHP). The announcement provides early-stage preclinical evaluation progress but does not include efficacy, timelines, or financial impact.